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2. ABSTRACT 
 
Background & Aims. Patients with chronic hepatitis C virus (HCV) infection may develop 
cirrhosis with portal hypertension, reflected by decreased platelet count and splenomegaly. 
This retrospective cohort study aimed to assess changes in platelet counts after antiviral 
therapy among chronic HCV-infected patients with advanced fibrosis.  
Methods. Platelet counts and spleen sizes were recorded in an international cohort of 
patients with Ishak 4-6 fibrosis who started antiviral therapy between 1990 and 2003. Last 
measured platelet counts and spleen sizes were compared to their pre-treatment values 
(within 6 six months prior to the start of therapy). All registered platelet count measurements 
from 24 week following cessation of antiviral therapy were included in repeated 
measurement analyses.   
Results. This study included 464 patients; 353 (76%) had cirrhosis and 187 (40%) attained 
sustained virological response (SVR). Among patients with SVR, median platelet count, 
increased by 35 x109/L (IQR 7-62, p<0.001). In comparison, patients without SVR showed a 
median decline of 17 x109/L (IQR -5-47, p<0.001). In a subgroup of 209 patients, median 
decrease in spleen size was 1.0 cm (IQR 0.3-2.0) for patients with SVR, while median 
spleen size increased with 0.6 cm (IQR -0.1-2.0, p<0.001) among those without SVR. The 
changes in spleen size and platelet count were significantly correlated (R=-0.41, p<0.001).  
Conclusions. Among chronic HCV-infected patients with advanced hepatic fibrosis the 
platelet counts improved following SVR and the change in platelets correlated with the 
change in spleen size following antiviral therapy. These results suggest that HCV eradication 
leads to reduced portal pressure. 
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3. MANUSCRIPT 
 
Introduction 
The continuous inflammation in livers of patients with chronic hepatitis C virus (HCV) 
infection may cause hepatic fibrogenesis. Progression of this process may eventually lead to 
cirrhosis, at which stage patients have an unfavorable prognosis due to the elevated risk of 
hepatocellular carcinoma (HCC) and liver failure.(1) In one of the largest studies on the 
fibrosis progression rate, dating back to 1997, it was estimated that 33% of patients with 
chronic HCV infection develop cirrhosis within 20 years.(2) However, the number of patients 
who develop cirrhosis could be higher over a longer period of time as fibrosis development 
may not be linear. In fact, as the population with chronic hepatitis C is aging, it is expected 
that the incidence of HCV-related cirrhosis will increase during the upcoming years.(3) 
The treatment of chronic HCV infection improved enormously during the last two 
decades. Even in case of advanced hepatic fibrosis, sustained virological response (SVR) 
rates over 90% can be achieved with combination regimens of direct-acting antiviral 
agents.(4-8) Several studies showed that hepatic fibrosis can regress once HCV is 
eradicated as causative agent of liver injury, also among patients with advanced hepatic 
fibrosis.(9-16) However, these studies are limited by a short follow-up duration or low 
number of patients with cirrhosis. Also, there is significant sampling error with respect to 
percutaneous liver biopsy, which remains an invasive procedure with potentially severe 
complications so that repeated assessments of liver histology are often not feasible.(16-18) 
The longitudinal pattern of hepatic fibrosis regression is thus difficult to study. 
The platelet count is strongly related to the degree of hepatic histopathological 
abnormalities and portal pressure, especially among those patients with bridging fibrosis or 
cirrhosis.(19-26) Indeed, lower platelets have been repeatedly associated with a higher risk 
for cirrhosis-related morbidity and mortality, which supports that the platelet count is 
representative of the stage of liver disease.(1, 27-29) Importantly, the change in platelets 
correlated with the change in hepatic fibrosis following antiviral therapy among patients with 
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chronic HCV infection, including those who attained SVR.(30, 31) Changes in platelets thus 
represent a non-invasive alternative to assess the evolution of the stage of liver disease and 
portal pressure. Because splenic sequestration of blood cells as a direct result of elevated 
portal pressure causes the spleen to increase in size, splenomegaly is also considered a 
non-invasive marker of the degree of portal hypertension or presence of esophageal 
varices.(22-24) 
The aim of our study was to assess the change in platelet counts following SVR in a 
large cohort of consecutively interferon-treated patients with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis.  
 
Patients and Methods 
All consecutive patients with chronic HCV infection and bridging fibrosis or cirrhosis 
(Ishak fibrosis score 4-6) who initiated interferon-based antiviral therapy between 1990 and 
2003 were included from 5 large hepatogy units in Europe and Canada. The design of this 
retrospective cohort study have been described in detail previously.(29) For the current 
study, the patients were assessed from the last received interferon-based treatment course 
onwards. Hereby it was prevented that interferon-induced bone marrow suppression 
influenced the platelet counts during follow-up as a result of retreatment. Excluded were 
patients with a human immunodeficiency virus or hepatitis B virus co-infection, patients who 
had developed HCC or liver failure prior to start of follow-up or prior to the first available 
platelet count measurement during follow-up, and patients who received long-term low-dose 
pegylated interferon maintenance therapy. Patients without follow-up beyond January 1st 
2010 were invited for a single visit to the outpatient clinic.  
The study was conducted in accordance with the guidelines of the Declaration of 
Helsinki and the principles of Good Clinical Practice. According to the standards of the local 
ethics committees, written informed consent was obtained from patients visiting the 
outpatient clinics.  
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Outcome measures 
Pre-treatment markers of liver disease severity closest to the start of therapy were 
included, as long as these were available within six months before the start of antiviral 
therapy. All available platelet count measurements were registered from 24 weeks after 
cessation of interferon-based antiviral therapy. A platelet count <150 x109/L was defined as 
thrombocytopenia. Measurements obtained after the diagnosis of HCC or liver failure were 
not considered. The diagnosis of HCC was based on histopathological confirmation or 2 
coincident imaging techniques (computed tomography, magnetic resonance imaging or 
contrast-enhanced ultrasonography) showing a focal lesion larger than 2 centimeters with 
arterial-phase hyper-enhancement or 1 imaging technique showing a focal lesion larger than 
2 centimeters with arterial-phase hyper-enhancement in the presence of an α-fetoprotein 
level greater than 400 ng/mL.(32) Liver failure was defined as an episode of ascites, 
bleeding varices, jaundice or overt hepatic encephalopathy. Only the first episode of liver 
failure was considered in case patients experienced multiple liver failure events. The last 
available spleen size measurement (in centimeters), as determined by radiological 
examination (ultrasound, computed tomography or magnetic resonance imaging), was 
registered. Spleen sizes which were measured after initiation of treatment for HCC or portal 
hypertension were not considered, and in such cases the last spleen size prior to these 
events was used.  
 
Statistical analyses 
Baseline characteristics were compared between patients with SVR and patients 
without SVR using the Mann-Whitney test for continuous and the chi-square test for 
categorical variables. To assess the difference in median platelet count per Ishak fibrosis 
scores (4, 5 or 6), the Kruskal–Wallis was used. Correlations were analyzed with 
Spearman's rank correlation coefficient. The relation between baseline laboratory markers 
and the degree of hepatic fibrosis (Ishak 4/5 versus 6 and Ishak 4 versus 5/6) was assessed 
with logistic regression and receiver operating characteristic curve analysis.  
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Per virological response group, the statistical significance of the change in platelets 
from baseline to the last available measurement during follow-up was assessed with the 
Wilcoxon signed-rank test. The difference in the change of platelets between patients with 
SVR and patients without SVR was assessed with the Mann-Whitney test. Per virological 
response group, McNemar’s test was used to assess the difference in the percentage of 
patients with thrombocytopenia at baseline and last follow-up. The change in spleen size 
was assessed accordingly. 
Linear regression analysis was used to determine which baseline variables were 
associated with the change in platelets from baseline to last follow-up among the patients 
who attained SVR. Repeated measurement analyses with a random intercept and slope per 
patient and an unstructured covariance matrix were performed to analyze the evolution of 
platelets over time, correcting for potential non-linearity by including the squared time to the 
platelet count measurement into the model. As chronic HCV infection and interferon therapy 
can influence the platelets as well, 24 weeks after cessation of antiviral therapy was 
considered as time zero in the repeated measurement analyses. 
All statistical tests were two-sided, and a p-value <0.05 was considered to be 
statistically significant. SPSS version 17.0.2 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 
PROC GENMOD (SAS institute, Cary, NC) were used for all statistical analyses. 
 
Results 
Study population 
Between 1990 and 2003, 546 patients with chronic HCV infection and histological 
proof of advanced hepatic fibrosis received interferon-based antiviral therapy. Eight patients 
who were lost-to-follow-up and 8 patients who developed HCC or liver failure before 24 
weeks after their initial treatment course were excluded. Of the remaining 530 patients, 
125(24%) attained SVR and 405(76%) did not. During follow-up 204 patients without SVR 
were retreated at least once, which resulted in SVR for another 67 patients. Among 
retreated patients, 7 experienced a cirrhosis-related complication before 24 weeks following 
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their last treatment course, 14 received long-term low dose pegylated interferon 
maintenance therapy, and 45 had no available platelet count measurement during follow-up. 
These patients were excluded as well, so that the total study cohort consisted of 464 
patients; 187 with SVR and 277 without SVR (Figure 1). Table 1 summarizes the baseline 
characteristics according to the virological response to the last antiviral treatment course. 
 
Platelet count in relation to hepatic fibrosis 
At baseline, platelet counts were associated with histological stage of fibrosis: the 
median platelet count was 186 x109/L (interquartile range [IQR] 143-226) among patients 
with Ishak fibrosis score 4, 160 x109/L (IQR 134-209) among patients with Ishak fibrosis 
score 5 and 133 x109/L (IQR 92-176) among patients with Ishak fibrosis score 6 (p<0.001). 
Accordingly, the percentage of patients with thrombocytopenia increased with higher Ishak 
fibrosis score (31%, 40% and 60% for Ishak fibrosis score 4, 5 and 6, respectively, p<0.001). 
The platelet count could largely discriminate patients with Ishak fibrosis score 4/5 from those 
with Ishak 6 (area under the curve [AUC] 0.70, 95% confidence interval [CI] 0.65-0.75, 
p<0.001). The AUC of the platelet count was similar to differentiate between Ishak 4 and 5/6 
(AUC=0.69, 95%CI 0.63-0.74, p<0.001). The discriminating abilities of bilirubin, albumin or 
the ratio between the aspartate and alanine aminotransferase were lower (AUCs ranging 
from 0.56 to 0.62). Logistic regression analyses indicated that the platelet count was the only 
objective laboratory marker of liver disease severity that had an independent statistically 
significant association with the baseline stage of hepatic fibrosis (Table 2). 
 
Changes in platelets following antiviral therapy 
During the follow-up which started 24 weeks post-treatment, 3387 platelet count 
measurements were registered. The median interval between platelet count measurements 
was 0.45 years (IQR 0.13-0.79), which differed between patients with SVR (0.54 years, IQR 
0.28-1.02) and patients without SVR (0.31 years, IQR 0.12-0.61, p<0.001). The last 
available platelet counts were measured after a median of 5.7 (IQR 2.1-7.6) years among 
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patients with SVR and after 4.4 (IQR 1.9-7.1) years among patients without SVR (p=0.111). 
The median last platelet count was 198 x109/L (IQR 166-248) in the group with SVR and 113 
x109/L (IQR 73-167) in the group without SVR (p<0.001). In 426 patients a platelet count 
measurement was available both at baseline as well as during follow-up. Among those with 
SVR, 44(62%) of the patients with thrombocytopenia at baseline showed a normal platelet 
count at the time of the last measurement (p<0.001), while only 2(2%) patients with SVR and 
normal platelets at baseline had thrombocytopenia at the final measurement (Table 3). The 
platelet counts in these patients were 122 x109/L and 134 x109/L at the end of follow-up, 
respectively. Among patients without SVR, 47(43%) patients changed from a normal platelet 
count at baseline to thrombocytopenia at the end of follow-up (p<0.001), while 14 (10%) 
patients with thrombocytopenia at baseline had normal platelet counts at the time of the last 
measurement. From baseline to the last available measurement, the platelet count showed a 
median increase of 35 x109/L (IQR 7-62) among the patients with SVR and a median 
decrease of 17 x109/L (IQR -5-47) among patients without SVR (p<0.001; for the paired 
analyses within each response group as well as for the comparison between both response 
groups).  
 Linear regression analyses were performed to assess which factors were associated 
with improvement of platelets following SVR (Table 4). Higher body mass index (BMI) was 
negatively associated with the change in the platelet count (β=-1.59, standard error 0.78, 
p=0.043). These analyses were corrected for the baseline platelet count and the time from 
SVR to the last platelet count measurement.   
Repeated measurement analyses showed a gradual and almost linear increase in 
platelets beyond the moment of SVR, while the platelet counts further declined among those 
patients who did not attain SVR (p<0.001; for the change within each response group as well 
as for the comparison between both response groups) (Figure 2). 
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Spleen size 
Spleen sizes were available within 6 months prior to initiation of antiviral therapy in 
99(53%) patients with SVR and 147(53%) patients without SVR. The median baseline 
spleen size was 12.0 cm (IQR 10.6-13.8) among those patients who would later achieve 
SVR and 12.9 (IQR 11.2-14.8) among those without subsequent SVR (p=0.012). The 
median spleen sizes were 11 cm (IQR 9.8-12.6), 12.5 cm (IQR 11.4-14.0) and 13.0 cm (IQR 
11.4-15.0) among patients with Ishak 4, 5 and 6 fibrosis, respectively (p<0.001). The AUC to 
discriminate Ishak 4/5 from Ishak 6 fibrosis using the spleen size was 0.65 (95%CI 0.58-
0.72, p<0.001) and 0.74 (95%CI 0.66-0.81, p<0.001) to discriminate Ishak 4 from Ishak 5/6. 
At baseline, the spleen size was significantly correlated to the platelet count (R=-0.44, 
p<0.001). 
In 145(78%) patients with SVR and 235(85%) of patients without SVR a spleen size 
was registered during follow-up. The last median spleen size was 10.4 cm (IQR 9.5-12.0) 
among patients with SVR versus 13.6 cm (IQR 11.6-16.0) among patients without SVR 
(p<0.001). Paired data on pre-treatment and end-of-follow-up spleen sizes were available in 
209(45%) patients. Among patients with SVR the spleen size showed a median decrease of 
1.0 cm (IQR 0.3-2.0) and among patients without SVR the spleen size showed a median 
increase of 0.6 cm (IQR -0.1-2.0) from baseline to the last measurement (p<0.001; for the 
paired analyses within each response group as well as for the comparison between both 
response groups). The change in spleen size was statistically significantly correlated with 
the change in platelet count (R=-0.41, p<0.001). 
 
Discussion 
 With this study we showed that the platelet counts improved following eradication of 
chronic HCV infection among patients with bridging fibrosis or cirrhosis. With a repeated 
measurement analysis including over 3000 platelet count evaluations, a rather linear 
increase in platelets was observed from the moment of SVR onwards. In contrast, patients 
who did not attain SVR showed a further decline. The increase in platelets continued for 
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many years after SVR, suggesting that the histopathological abnormalities and portal 
pressure gradually improve among chronic HCV-infected patients with advanced liver 
disease who were successfully treated. This was further substantiated by the reduction in 
spleen size among the patients who had attained SVR.  
 Four previous studies have assessed the change in platelets after SVR among 
Western patients with chronic HCV infection.(10, 33-35) George et al. followed 150 patients 
with interferon-induced clearance of their chronic HCV infection for 5 years.(10) In this study 
the mean pre-treatment platelet count (232 x109/L) did not significantly differ from the mean 
last measured platelet count during follow-up (235 x109/L). However, only 16 (11%) patients 
with cirrhosis were included in this study, at which stage platelet counts are most affected. 
Although limited by the inclusion of only 10 (10%) patients with cirrhosis as well, another 
follow-up study did show that the mean platelets significantly increased from 209 x109/L at 
baseline to 239 x109/L at the final follow-up (which ranged from 1 to 22 years after 
successful therapy) among 100 patients with SVR.(34) The change in platelets following 
antiviral therapy was also assessed in the Hepatitis C Antiviral Long-Term Treatment 
Against Cirrhosis (HALT-C) trial, which only included patients with at least Ishak F3 
fibrosis.(28) In contrast to both above-described studies, a control group without SVR was 
included. As compared to pre-treatment levels, the mean platelet count was already 
significantly increased at the time SVR was attained (24 weeks after cessation of therapy). 
An additional post-hoc assessment among the patients with SVR after approximately 5 
years of follow-up indicated that the platelet counts further increased with time. In line with 
our findings, the platelet counts declined among patients without SVR.  
With repeated measurement analyses including all platelet count assessments during 
follow-up, we have showed the evolution of platelets according to the virological response 
following antiviral therapy among patients with bridging fibrosis or cirrhosis in more detail. 
Pre-treatment platelet counts were not included in these analyses as we started the follow-
up at the time of SVR. This is important, because other mechanisms than splenic 
sequestration as a result of elevated portal pressure may reduce the platelet counts among 
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patients with chronic HCV infection as well, such as reduced thrombopoietin (TPO) 
production, HCV-mediated bone marrow suppression and the presence of autoantibodies, 
causing chronic immune thrombocytopenic purpura.(36) At the time of SVR, when HCV has 
been suppressed for more than 6 months, bone marrow suppression due to HCV or 
interferon-based therapy should no longer be of influence.(37, 38) Increasing TPO levels 
could continue to be relevant for the rise of platelets after SVR, since the production of TPO 
has been negatively correlated with the degree of hepatic fibrosis.(39, 40) In this case 
regression of hepatic fibrosis and improvement of liver function would thus remain the 
underlying cause for the improved platelet counts. Nevertheless, lowering of portal pressure 
and reversal of splenomegaly is likely to remain a predominant reason for the increase in 
platelets once HCV is eradicated as cause of liver injury. Indeed, the change in platelets and 
change in spleen size were correlated in our study, which has not been shown by any of the 
previous studies. A limitation of the current study, however, is that data on baseline spleen 
size were available in only a limited number of the included patients, also because we 
restricted the baseline period to 6 months prior to the start of antiviral therapy. 
 Another interesting result of our study was that higher BMI was negatively associated 
with the increase in platelet counts among the patients with SVR. Currently, risk factors for 
disease progression following viral eradication remain largely unknown. Our finding might be 
explained by the presence of hepatic steatosis and inflammation among patients with high 
BMI.(41, 42) Although data on the presence of steatosis is lacking in our cohort, its 
association with higher BMI is well known.(43) To what extend these or other aspects of the 
metabolic syndrome may impact the clinical course of cirrhosis after patients have cleared 
their chronic HCV infection requires further study. For now, life-style modifications to reduce 
obesity may be advocated.(44) 
Despite the limitations of percutaneous liver biopsy (ethical concerns regarding 
multiple measurements and the subjective character of hepatic fibrosis assessment), the 
impact of antiviral therapy on liver histology among patients with chronic HCV infection has 
been studied.(9, 10, 15, 16, 45) The largest study to date included almost 700 patients with 
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at least METAVIR F2 fibrosis at baseline from 4 randomized controlled trials.(15) Even 
though all patients were biopsied already 24 weeks after cessation of antiviral therapy, 
patients with SVR showed regression of hepatic fibrosis while patients without SVR had 
rather stable liver disease, with median estimated annual METAVIR fibrosis progression 
rates of -0.591 and 0, respectively. However, 24 weeks after cessation of antiviral therapy 
might too early to assess the true impact of successful antiviral therapy on liver histology. 
Indeed, a prior study including 183 patients with various degrees of HCV-induced hepatic 
fibrosis and SVR indicated that regression of hepatic fibrosis takes time, as the regression of 
fibrosis was more pronounced in case of longer post-SVR follow-up.(16) Our data, showing 
the continued increase in platelets for many years after SVR, is in line with this finding. A 
recent histological study including patients with HCV-related cirrhosis and SVR showed that 
23 (61%) patients had a reduction of the METAVIR F4 fibrosis score in their liver biopsy 
obtained after a median of approximately 5 years following treatment cessation.(9) 
Interestingly, even though the METAVIR F4 score was not reduced in the remaining 15 
(39%) patients, morphometric analyses indicated that their total liver collagen content was 
still significantly reduced. Because the semi-quantitative hepatic fibrosis scores, by which 
regression of hepatic fibrosis has been largely assessed so far, may thus be somewhat too 
crude, objective and continuous variables for the assessment of changes in hepatic fibrosis 
are relevant to fully appreciate the impact of SVR on liver disease severity. As the change in 
platelets has been linked to the change in hepatic fibrosis, the platelet count represents an 
easily accessible biomarker to assess histological improvement.(30, 31) We remained with 
the platelet count as outcome measure in our study because many other laboratory-based 
non-invasive fibrosis markers showed a poor accuracy for hepatic fibrosis assessment 
among patients with SVR.(46) Perhaps this is explained by the fact that most include 
parameters of hepatic inflammation, which is also affected by viral eradication. 
Regression of hepatic fibrosis, especially in case of cirrhosis, was recently shown to 
be clinically relevant. In a pivotal study by Mallet et al. clinical outcome was superior among 
chronic HCV-infected patients with cirrhosis who showed a substantial reduction of their 
 This article is protected by copyright. All rights reserved. 
post-treatment METAVIR score as compared to patients who did not regress.(11) In 
addition, other large cohort studies have indicated that SVR was also associated with a 
reduced occurrence of liver failure, HCC and mortality among patients with advanced liver 
disease.(27-29, 47-49) Only a few studies have directly measured the hepatic venous 
pressure gradient (HVPG) before and after antiviral therapy.(50-52) All included only a small 
number of patients, but showed that SVR was significantly associated with a reduction in 
HVPG, which remains one of the best validated surrogate markers in hepatology. Our 
finding of a decrease in spleen size following SVR in a large group of patients with bridging 
fibrosis or cirrhosis further substantiates the reduction of portal pressure once the chronic 
HCV infection is eradicated.  
In conclusion, the platelet counts gradually increased and the spleen size decreased 
following achievement of SVR among chronic HCV-infected patients with bridging fibrosis or 
cirrhosis. This suggests that successful antiviral therapy leads to a reduction in portal 
pressure, probably due to regression of the histopathological abnormalities which have 
resulted from long-term liver injury due to chronic HCV infection.  
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Table 1. Baseline characteristics according to virological response 
 
Data are presented as median (interquartile range), unless otherwise noted. Abbreviations: BMI; Body Mass 
Index, HCV; Hepatitis C Virus, IFN; interferon, pegIFN; pegylated interferon, AST; Aspartate aminotransferase, 
ALT; Alanine aminotransferase, antiHBc; anti-hepatitis B core antigen, PI; protease inhibitor.  
a
 BMI was missing in 24 (13%) patients with SVR, and 61 (22%) patients without SVR. 
b
 Platelet count was missing in 9 (5%) patients with SVR and 29 (10%) patients without SVR. Albumin was 
missing in 13 (7%) patients with SVR and 48 (17%) patients without SVR. Total bilirubin was missing in 14 (7%) 
patients with SVR and 36 (13%) patients without SVR. The AST/ALT ratio was missing in 15 (8%) patients with 
SVR and 37 (15%) patients without SVR. The spleen size was missing in 88 (47%) patients with SVR and 130 
(47%0 patients without SVR. 
c
 Severe alcohol use was defined as the use of more than 50 gram of alcohol per day. 
 
Overall 
(n = 464) 
With SVR 
(n = 187) 
Without SVR 
(n = 277) 
p-value 
Age, years 51 (44-57) 49 (44-57) 51 (44-58) 0.071 
Male, n/total (%) 321/464 (69) 137/187 (73) 184/277 (66) 0.118 
BMI, kg/m
2
 
a
 25.9 (23.4-28.7) 25.6 (23.1-28.6) 26.1 (23.8-29.0) 0.135 
Fibrosis score, n/total (%)    0.429 
    - Ishak 4 111/464 (24) 50/187 (27) 61/277 (22)  
    - Ishak 5 91/464 (20) 33/187 (18) 58/277 (21)  
    - Ishak 6 262/464 (56) 104/187 (55) 158/277 (57)  
HCV genotype, n/total (%)     <0.001 
    - 1 300/440 (68) 93/179 (52) 207/261 (79)  
    - 2 42/440 (10) 32/179 (18) 10/261 (4)  
    - 3 79/440 (18) 46/179 (26) 33/261 (13)  
    - 4 15/440 (3) 6/179 (3) 9/261 (3)  
    - Other 4/440 (1) 2/179 (1) 2/261 (1)  
Type of treatment, n/total (%)    <0.001 
    - IFN mono 70/464 (15) 9/187 (5) 61/277 (22)  
    - IFN and RBV 110/464 (24) 49/187 (26) 61/277 (22)  
    - pegIFN mono 12/464 (3) 4/187 (2) 8/277 (3)  
    - pegIFN and RBV 253/464 (54) 118/187 (63) 135/277 (49)  
    - ConsensusIFN (+/- RBV) 11/464 (2) 2/187 (1) 9/277 (3)  
    - pegIFN and RBV and PI 8/464 (2) 5/187 (3) 3/277 (1)  
Laboratory markers of liver disease 
severity 
b
 
    
    - Platelet count, x10
9
/L  150 (112-199) 162 (132-205) 142 (100-191) <0.001 
    - Albumin, g/L 42 (39-44) 42 (40-44) 41 (38-44) 0.016 
    - Bilirubin, μmol/L 13 (10-18) 12 (9-15) 14 (10-19) <0.001 
    - AST/ALT ratio 0.73 (0.59-0.92) 0.68 (0.55-0.82) 0.76 (0.62-0.97) <0.001 
Spleen size, cm 12.5 (11.0-14.3) 12.0 (10.6-13.8) 12.9 (11.2-14.8) 0.012 
Treatment naïve, n/total (%) 267/464 (58) 109/187 (58) 158/277 (57)  0.789 
Year treatment started 2001 (1998-2003) 2002 (2000-2003) 2001 (1998-2003) 0.003 
Treatment duration, weeks 31 (22-48) 48 (25-49) 24 (16-48) <0.001 
Diabetes mellitus, n/total (%)  71/464 (15) 20/187 (11) 51/277 (18) 0.024 
History of severe alcohol use, n/total (%)
 c
 100/437 (23) 38/180 (21) 62/257 (24) 0.460 
AntiHBc positivity, n/total (%) 168/364 (46) 63/141 (45) 105/223 (47) 0.654 
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Table 2. Logistic regression analyses for the stage of hepatic fibrosis 
 
Abbreviations: ALT; Alanine aminotransferase, AST; Aspartate aminotransferase, BMI; Body mass index, HCV; 
hepatitis C virus, CI; Confidence interval, OR; Odds Ratio.  
  
Ishak score 4 versus 5/6 
Univariate analyses Multivariate analyses 
OR 95%CI p-value OR 95%CI p-value 
Age, per year 1.05 1.02-1.07 <0.001 1.05 1.02-1.08 0.003 
Males 1.17 0.74-1.84 0.511 - - - 
BMI, per kg/m
2
 1.07 1.00-1.13 0.036 1.05 0.98-1.11 0.150 
HCV genotype 3 1.53 0.89-2.63 0.121 - - - 
Laboratory data       
- Platelet count, per 10x10
9
/L 0.92 0.89-0.96 <0.001 0.93 0.89-0.97 0.001 
- Albumin, per g/L 0.94 0.89-0.99 0.012 0.98 0.91-1.05 0.505 
- Bilirubin, per μmol/L 1.04 1.00-1.07 0.037 1.00 0.97-1.04 0.817 
- AST/ALT ratio, per 0.1 1.01 0.96-1.06 0.713 - - - 
Diabetes mellitus 1.66 0.86-3.21 0.135 - - - 
History of severe alcohol use 1.17 0.70-1.94 0.546 - - - 
AntiHBc positivity 0.93 0.57-1.51 0.760 - - - 
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Table 3. Thrombocytopenia at baseline versus follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
Included in these analyses were all 426 patients (178 with SVR and 248 without SVR) who had both a platelet 
count measurement at baseline and a platelet count measurement during follow-up available. The grey-shaded 
cells indicate the groups of patients who showed a change in platelet count category from baseline to the last 
measurement during follow-up. Platelets are measured in x10
9
/L. 
  
Patients with SVR Last platelets <150 Last platelets ≥150 total 
Baseline platelets <150 27 (38%) 44 (62%) 71 
Baseline platelets ≥150 2 (2%) 105 (98%) 107 
total 29 (16%) 149 (84%) 178 
 McNemar’s test: p<0.001 
    
Patients without SVR Last platelets <150 Last platelets ≥150 total 
Baseline platelets <150 124 (90%) 14 (10%) 138 
Baseline platelets ≥150 47 (43%) 63 (57%) 110 
total 171 (69%) 77 (31%) 248 
 McNemar’s test: p<0.001 
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Table 4. Linear regression analyses for the change in platelets among patients with 
SVR a 
 
Abbreviations: ALT; Alanine aminotransferase, AST; Aspartate aminotransferase, BMI; Body mass index, HCV; 
hepatitis C virus, SE; Standard error.  
a
 The unstandardized coefficients are reported. 
b
 The β indicates that for each unit increase of the predictor variable, the change in platelets will increase (in case 
of a positive β) or decrease (in case of a negative β) by β units. So, when specified to our multivariate analysis 
above, for every 1 kg/m
2
 increase in BMI at baseline, the change in platelets will be 1.59 x10
9
/L lower.  
  
SVR patients 
Univariate analyses Multivariate analyses 
β 
b
 SE p-value β
 b
 SE p-value 
Age, per year 0.36 0.35 0.307 - - - 
Males -3.88 7.46 0.603 - - - 
BMI, per kg/m
2
  -1.75 0.83 0.037 -1.59 0.78 0.043 
Ishak score 4 vs. 5/6 -1.90 7.37 0.797 - - - 
HCV genotype 3 0.81 7.80 0.917 - - - 
Laboratory markers at baseline       
    - Platelet count, per 10x10
9
/L  -1.43 0.53 0.007 -1.84 0.05 0.001 
    - Albumin, per g/L -0.44 0.83 0.596 - - - 
    - Bilirubin, per μmol/L 0.10 0.46 0.835 - - - 
    - AST/ALT ratio, per 0.1 -1.51 1.13 0.183 - - - 
Diabetes mellitus  16.78 10.65 0.117 - - - 
History of severe alcohol use -9.62 8.27 0.246 - - - 
Time to last platelet count, per 
year 
3.46 0.92 <0.001 3.37 0.99 0.001 
AntiHBc positivity 13.11 7.87 0.098 - - - 
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Figure 1. Study flow chart 
Abbreviations: HCC; hepatocellular carcinoma, SVR; sustained virological response, 
pegIFN; pegylated interferon 
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Figure 2. Evolution of platelet counts according to virological response 
Repeated measurement analyses with a random intercept and slope per patient and an 
unstructured covariance matrix were performed to analyze the evolution of platelets over 
time, correcting for potential non-linearity by including the squared time to the platelet count 
measurement into the model. The mean and 95% confidence interval (dotted line) are 
presented for patients with sustained virological response (SVR) and patients without SVR. 
Twenty-four weeks after cessation of antiviral therapy was considered as time 0. The 
statistical significance refers to both the change within the group with SVR, the change 
within the group without SVR as well as the difference between both virological response 
groups. 
